GNML.F Stock Overview
Provides pharmaceutical and personal care products primarily in Latin America. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 3/6 |
Genomma Lab Internacional, S.A.B. de C.V. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | Mex$1.27 |
| 52 Week High | Mex$1.28 |
| 52 Week Low | Mex$0.79 |
| Beta | 0.48 |
| 11 Month Change | 12.39% |
| 3 Month Change | 29.59% |
| 1 Year Change | 51.21% |
| 33 Year Change | 46.82% |
| 5 Year Change | 17.57% |
| Change since IPO | -34.87% |
Recent News & Updates
Recent updates
Shareholder Returns
| GNML.F | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | -0.4% | 1.6% | 2.2% |
| 1Y | 51.2% | 9.9% | 31.6% |
Return vs Industry: GNML.F exceeded the US Pharmaceuticals industry which returned 9.9% over the past year.
Return vs Market: GNML.F exceeded the US Market which returned 31.6% over the past year.
Price Volatility
| GNML.F volatility | |
|---|---|
| GNML.F Average Weekly Movement | n/a |
| Pharmaceuticals Industry Average Movement | 9.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: GNML.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine GNML.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 1,614 | Juan Marco Sparvieri | www.genommalab.com |
Genomma Lab Internacional, S.A.B. de C.V., together with its subsidiaries, provides pharmaceutical and personal care products primarily in Latin America. It develops, sells, and markets a range of branded products in the categories of anti-acne products, self-diagnosis, antibacterial, cream to improve the texture of scarred skin, shampoos, dandruff shampoos, soaps, razors, products to prevent hair loss, ointment for muscle pain, anti-fungal treatments for the relief of colitis, products to counter stress levels, anti-wrinkles, antacids, anti-ulcers, anti-flu, protection and sexual improvement, treatments against hemorrhoids, against varicose veins, osteoarthritis, ophthalmic medications, and infant nutrition. The company was incorporated in 1996 and is based in Mexico City, Mexico.
Genomma Lab Internacional, S.A.B. de C.V. Fundamentals Summary
| GNML.F fundamental statistics | |
|---|---|
| Market cap | US$1.21b |
| Earnings (TTM) | US$78.25m |
| Revenue (TTM) | US$852.83m |
15.5x
P/E Ratio1.4x
P/S RatioIs GNML.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| GNML.F income statement (TTM) | |
|---|---|
| Revenue | Mex$17.47b |
| Cost of Revenue | Mex$6.36b |
| Gross Profit | Mex$11.10b |
| Other Expenses | Mex$9.50b |
| Earnings | Mex$1.60b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.70 |
| Gross Margin | 63.56% |
| Net Profit Margin | 9.18% |
| Debt/Equity Ratio | 59.1% |
How did GNML.F perform over the long term?
See historical performance and comparison